<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911030-0015</DOCNO><DOCID>911030-0015.</DOCID><HL>   International Brief -- SmithKline Beecham PLC:   Pretax Profit Climbed 16%,   Sales Rose 8.8% in Quarter</HL><DATE>10/30/91</DATE><SO>WALL STREET JOURNAL (J), PAGE A12</SO><CO>   SBE</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)EARNINGS (ERN)</IN><NS>EARNINGS (ERN)</NS><RE>EUROPE (EU)GREAT BRITAIN (UK)WESTERN EUROPE (WEU)</RE><LP>   SmithKline Beecham PLC said pretax profit rose 16% in thethird quarter, reflecting a 15% rise in profit fromcontinuing operations.   Pretax profit rose to #252 million ($426.9 million) from#218 million, as sales climbed 8.8% to #1.17 billion from#1.08 billion.</LP><TEXT>   SmithKline's results were at the upper end of marketforecasts, which analysts said would highlight unspectacularbut consistent sales growth, improved margins and reducedgroup debt.   All divisions recorded gains in pretax profit, except forconsumer brands; the company said that division was hurt bythe recession in the U.S. and U.K. Pharmaceuticals, thegroup's main profit center, had pretax profit of #157million, up from #120 million a year earlier. Sales rose to#587 million from #507 million.   SmithKline's chief executive officer, Robert P. Bauman,said that &quot;difficulties experienced by our pharmaceuticalsbusiness in Italy, Japan and the Middle East over the firstsix months of the year are easing.&quot; He added, &quot;We expect thisencouraging performance to continue for the full year.&quot;</TEXT></DOC>